Shanghai Henlius Biotech has announced a licensing deal for three biosimilars – bevacizumab, rituximab and trastuzumab – with Brazil’s Eurofarma. The agreement, which could be worth as much as $50.5m, gives the Chinese company enhanced access to Latin America as it continues to broaden its global footprint.
Henlius will broaden access to markets in Latin America through the alliance with Brazil’s Eurofarma • Source: Shutterstock
Shanghai Henlius Biotech has struck a deal with Brazil’s Eurofarma worth as much as $50.5m that will see three of its biosimilars marketed by the Brazilian firm in 16 Latin American countries.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
The company did not disclose which particular drugs it secured through the deal that further boosted its portfolio that already includes more than 100 assets.
Following recent agreements signed by Hikma and Amneal, Viatris has become the latest company to reach a cash settlement resolving allegations that its practices fuelled the US’ deadly opioid epidemic.
Organon has swelled its immunology biosimilar portfolio after acquiring the US commercial rights to Bio-Thera’s tocilizumab biosimilar from Biogen, which last year decided to retain its interests in biosimilars following a lengthy strategic review.
Partnering opportunities, paused marketing, approvals, litigations, and many more. Formycon sets out the agenda for 2025, after seeing a bumpy start to the year.
South Korea’s Celltrion has doubled down on its efforts in further building its pipeline, eyeing a target of 22 commercialized products by 2030 while also aiming to submit INDs for 13 novel compounds.
Samsung Bioepis and Teva have provided clarity on the pricing of their Epysqli biosimilar to Soliris in the US, as the firms launched only the second rival to the rare diseases treatment.
